Trading Ideas https://www.benzinga.com/views/taxonomy/term/22 en 5 Stocks Moving In Tuesday's After-Hours Session https://www.benzinga.com/news/earnings/19/10/14640832/5-stocks-moving-in-tuesdays-after-hours-session <h3>Gainers</h3> <ul> <li><strong>Teradyne, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ter#NASDAQ">TER</a>) shares are higher by 5% after reporting a third-quarter earnings beat. Earnings came in at 77 cents per share, beating estimates by 7 cents. Sales came in at $582 million, beating estimates by $19.28 million.</li> </ul> <h3>Losers</h3> <ul> <li><strong>Texas Instruments Incorporated</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/txn#NASDAQ">TXN</a>) shares are down 9% despite reporting a third-quarter earnings beat. Adjusted earnings came in at $1.49, beating estimates ...</li></ul><p><a href=https://www.benzinga.com/news/earnings/19/10/14640832/5-stocks-moving-in-tuesdays-after-hours-session alt=5 Stocks Moving In Tuesday&#039;s After-Hours Session>Full story available on Benzinga.com</a></p> CMG Earnings News SIX SNAP TER TXN After-Hours Center Movers Trading Ideas CMG US1696561059 TER US8807701029 TXN US8825081040 SIX US83001A1025 SNAP News Earnings After-Hours Center Movers Trading Ideas Benzinga Tue, 22 Oct 2019 21:20:11 +0000 Brett Hershman 14640832 at https://www.benzinga.com 15 Stocks Projected To Have The Biggest 5-Year EPS Declines https://www.benzinga.com/general/education/19/10/14639078/15-stocks-projected-to-have-the-biggest-5-year-eps-declines <p>Each earnings season, traders obsess over two numbers above all else: EPS and revenue. But seasoned traders know share prices often respond to the direction of EPS and revenue growth rather than their magnitude and size.</p> <p>A company with a low price-to-earnings ratio may look cheap to value investors at first glance. But if its EPS is declining over time, it could be a major red flag that something is fundamentally wrong with a company&rsquo;s business model. Companies can milk earnings from businesses in secular decline for years, but those earnings declines almost always catch up to investors eventually.</p> <h3>Largest Projected EPS Declines</h3> <p>Many stocks experience ...</p><p><a href=https://www.benzinga.com/general/education/19/10/14639078/15-stocks-projected-to-have-the-biggest-5-year-eps-declines alt=15 Stocks Projected To Have The Biggest 5-Year EPS Declines>Full story available on Benzinga.com</a></p> ADM COP DLPH DO FE HFC KHC NKTR NUE NWL PLD PSX SLG STT WDC Education Top Stories Trading Ideas General NKTR US6402681083 ADM US0394831020 COP US20825C1045 DO US25271C1027 FE US3379321074 NUE US6703461052 NWL US6512291062 PLD US74340W1036 SLG US78440X1019 STT US8574771031 WDC US9581021055 HFC DLPH PSX KHC Education Top Stories Trading Ideas General Benzinga Tue, 22 Oct 2019 21:00:22 +0000 Wayne Duggan 14639078 at https://www.benzinga.com BRP Group IPO: What You Need To Know https://www.benzinga.com/news/19/10/14636462/brp-group-ipo-what-you-need-to-know <p>This insurance and risk management company considers itself a pretty safe bet.</p> <h3><strong>The IPO</strong></h3> <p><a href="https://baldwinriskpartners.com/">BRP Group, Inc.</a> this week will issue 16.4 million shares on the Nasdaq under ticker &quot;BRP,&quot; according to the firm&rsquo;s <a href="https://www.sec.gov/Archives/edgar/data/1781755/000119312519270438/d220886ds1a.htm">S-1 filing</a>. Priced between $14 and $16, the offering represents 100% of outstanding shares and is expected to raise about $301.8 million.</p> <p>The lead underwriters are ...</p><p><a href=https://www.benzinga.com/news/19/10/14636462/brp-group-ipo-what-you-need-to-know alt=BRP Group IPO: What You Need To Know>Full story available on Benzinga.com</a></p> BRP News Previews IPOs Trading Ideas BRP CA11283W1041 News Previews IPOs Trading Ideas Benzinga Tue, 22 Oct 2019 20:00:31 +0000 Elizabeth Balboa 14636462 at https://www.benzinga.com PreMarket Prep: A Biotech Surprise, Stamps Shorts Take A Licking, Debating McDonald's Earnings Move https://www.benzinga.com/trading-ideas/long-ideas/19/10/14639048/premarket-prep-a-biotech-surprise-stamps-shorts-take-a-licking-debating-mcdonalds-earnin <p>Two major new stories dominated Tuesday&#39;s <a href="http://premarket.benzinga.com/pre-market-show/">PreMarket Prep Show</a>, and for good reason.</p> <p>The top story:&nbsp;<strong>Biogen </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/biib#NASDAQ">BIIB</a>) pulled a fast one on investors who threw in the towel on the company based on the March news that it had&nbsp;discontinued trials for its <a href="https://www.benzinga.com/general/biotech/19/10/14635164/biogen-plans-filing-for-failed-alzheimers-drug-after-new-analysis">Alzheimer&#39;s drug aducanumab</a>.</p> <p>The other story:&nbsp;<strong>Stamps.com</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stmp#NASDAQ">STMP</a>) reported a new collaboration with <strong>United Parcel Service</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ups#NYSE">UPS</a>) to provide its customer base with specially discounted UPS shipping rates.</p> <h3>Wasn&#39;t Alzheimer&#39;s Study Discontinued In March?&nbsp;</h3> <p>Before the open, Biogen announced a third-quarter EPS and sales beat &mdash; and its plans for a regulatory filing for aducanumab following new analysis.</p> <p>The company said its Phase 3 EMERGE study met its primary endpoint, and Biogen is now&nbsp;confident that a subset of patients in the trial study support the EMERGE findings.&nbsp;</p> <p>Since the issue has had several whipsaws off the news regarding this drug, the PreMarket Prep co-hosts viewed the spike as a selling opportunity for a few different reasons.</p> <p>First, and most importantly, there is no guarantee the drug will be approved by the FDA and brought to the market.</p> <p>When the issue has spiked on aducanumab in the past, it has faded over the long-term.&nbsp;</p> <p>The ...</p><p><a href=https://www.benzinga.com/trading-ideas/long-ideas/19/10/14639048/premarket-prep-a-biotech-surprise-stamps-shorts-take-a-licking-debating-mcdonalds-earnin alt=PreMarket Prep: A Biotech Surprise, Stamps Shorts Take A Licking, Debating McDonald&#039;s Earnings Move>Full story available on Benzinga.com</a></p> BIIB Chris Temple Long Ideas MCD News Nic Chahine PreMarket Prep STMP The National Investor UPS Short Ideas Trading Ideas BIIB US09062X1037 STMP US8528572006 MCD US5801351017 UPS US9113121068 Long Ideas News Short Ideas Trading Ideas Benzinga Tue, 22 Oct 2019 19:55:55 +0000 Joel Elconin 14639048 at https://www.benzinga.com Buckingham Bullish On Owens Corning Ahead Of Q3 Earnings Print https://www.benzinga.com/analyst-ratings/analyst-color/19/10/14636839/buckingham-bullish-on-owens-corning-ahead-of-q3-earnings-print <p>Roofing company <strong>Owens Corning</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/oc#NYSE">OC</a>) is expected to discuss on its third-quarter conference call signs of an improving residential end market, according to Buckingham.</p> <h3>The Analyst</h3> <p>Buckingham Research Group analyst <a href="https://www.tipranks.com/analysts/megan-mcgrath">Megan McGrath</a> upgraded Owens Corning from Neutral to Buy with a price target lifted from $59 to $79.</p> <h3>The Thesis</h3> <p>McGrath said the case for turning bullish on Owens Corning&#39;s stock isn&#39;t based on exceptions for a strong third quarter, but rather due to longer-term trends. Specifically, the company&#39;s insulation business should show signs of momentum in Wednesday&#39;s earnings print but will improve in 2020 from a lack of curtailment expenses, better U.S. volumes and potential ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/19/10/14636839/buckingham-bullish-on-owens-corning-ahead-of-q3-earnings-print alt=Buckingham Bullish On Owens Corning Ahead Of Q3 Earnings Print>Full story available on Benzinga.com</a></p> Analyst Color Buckingham construction Megan McGrath OC Roofing Upgrades Price Target Previews Analyst Ratings Trading Ideas OC US6907421019 Analyst Color Upgrades Price Target Previews Analyst Ratings Trading Ideas Benzinga Tue, 22 Oct 2019 18:09:07 +0000 Jayson Derrick 14636839 at https://www.benzinga.com Has The 737 Max Put Boeing's Dividend At Risk? https://www.benzinga.com/analyst-ratings/analyst-color/19/10/14638600/has-the-737-max-put-boeings-dividend-at-risk <p><strong>Boeing Co </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ba#NYSE">BA</a>) shares are down 11% in the past six months as the problems that grounded the 737 Max have proven more difficult to solve than many investors anticipated. Fortunately for Boeing bulls, one analyst said at least patient investors will likely continue to get paid to wait.</p> <h3>The Analyst</h3> <p>Bank of America analyst <a href="https://www.tipranks.com/analysts/ronald-epstein">Ronald Epstein</a> reiterated his Neutral rating and $370 price target for Boeing.</p> <h3>The Thesis</h3> <p>Boeing shares took a big hit last Friday after the FAA reported <a href="https://www.benzinga.com/government/19/10/14622672/faa-concerned-about-boeing-text-messages-that-may-indicate-company-misled-agency-on-737-max">&ldquo;concerning&rdquo; instant messages </a>between two Boeing employees that took place during the original certification of the 737 Max back in 2016. In response, Epstein lowered his price target for Boeing from $400 to $370 on Monday, noting that corporate governance concerns could ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/19/10/14638600/has-the-737-max-put-boeings-dividend-at-risk alt=Has The 737 Max Put Boeing&#039;s Dividend At Risk?>Full story available on Benzinga.com</a></p> 737 MAX Analyst Color BA Bank of America Ronald Epstein Dividends Price Target Reiteration Top Stories Analyst Ratings Trading Ideas BA US0970231058 Analyst Color Dividends Price Target Reiteration Top Stories Analyst Ratings Trading Ideas Benzinga Tue, 22 Oct 2019 17:40:54 +0000 Wayne Duggan 14638600 at https://www.benzinga.com Stamps.com Option Traders Hit The Jackpot On UPS News https://www.benzinga.com/news/19/10/14638065/stamps-com-option-traders-hit-the-jackpot-on-ups-news <p><strong>Stamps.com Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stmp#NASDAQ">STMP</a>) shares jumped higher by more than 22% on Tuesday after the company announced a <a href="https://www.ft.com/content/9c69ab70-f449-11e9-a79c-bc9acae3b654">new partnership</a> with <strong>United Parcel Service, Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ups#NYSE">UPS</a>).</p> <p>As part of the new partnership, Stamps.com at-home printing services will include discounted shipping rates due to its inclusion in the new UPS Digital Access Program. Stamps.com users will get up to 55% discounts on daily shipping rates and will not be subject to various surcharges.</p> <h3>Options Winners</h3> <p>While Stamps.com investors cheered the news, some large options hit the jackpot on Tuesday:</p> <ul> <li>Oct. 25 Stamps.com calls with an $85 strike price and 193 open interest gained 2,683%.</li> <li>Nov. 15 Stamps.com calls with an $80 strike price and 319 open interest gained 193.3%.</li> <li>Nov. 15 Stamps.com calls with an $85 strike price and 267 open interest gained 336.0%.</li> <li>Nov. 15 Stamps.com calls with a $90 strike price and 782 open interest gained 306.6%.</li> <li>Jan. ...</li></ul><p><a href=https://www.benzinga.com/news/19/10/14638065/stamps-com-option-traders-hit-the-jackpot-on-ups-news alt=Stamps.com Option Traders Hit The Jackpot On UPS News>Full story available on Benzinga.com</a></p> News STMP UPS Contracts Options Top Stories Markets Trading Ideas STMP US8528572006 UPS US9113121068 News Contracts Options Top Stories Markets Trading Ideas Benzinga Tue, 22 Oct 2019 16:30:10 +0000 Wayne Duggan 14638065 at https://www.benzinga.com Vertex Shares Are Rallying: What You Need To Know https://www.benzinga.com/general/biotech/19/10/14636557/vertex-shares-are-rallying-what-you-need-to-know <p><strong>Vertex Pharmaceuticals Incorporated </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrtx#NASDAQ">VRTX</a>) shares were off&nbsp;to a flying start Tuesday, extending the late-session surge from Monday that followed&nbsp;a positive FDA verdict.</p> <p>From around $177 at 2:40 p.m.&nbsp;Monday, the stock rallied strongly into the close, ending the session at $183.53, slightly off the intraday high of $184.81.&nbsp;</p> <p>The momentum was continuing in Tuesday&#39;s session.&nbsp;</p> <h3>What Happened</h3> <p>The FDA approved Vertex&#39;s&nbsp;Trikafta &mdash; a triplet comprising elexacaftor, tezacaftor and ivacaftor &mdash;&nbsp;for the treatment of cystic fibrosis in people&nbsp;ages 12 and older who have at least one F508del mutation in the CFTR gene, which is the most common cystic fibrosis-causing mutation.</p> <p>Trikafta is Vertex&#39; fourth approved ...</p><p><a href=https://www.benzinga.com/general/biotech/19/10/14636557/vertex-shares-are-rallying-what-you-need-to-know alt=Vertex Shares Are Rallying: What You Need To Know>Full story available on Benzinga.com</a></p> Biotech News Semma Therapeutics Trikafta VRTX FDA Top Stories Movers Trading Ideas VRTX US92532F1003 News Biotech FDA Top Stories Movers Trading Ideas Benzinga Tue, 22 Oct 2019 14:56:28 +0000 Shanthi Rexaline 14636557 at https://www.benzinga.com An Exponential Idea For Blockchain Exposure https://www.benzinga.com/markets/cryptocurrency/19/10/14632013/an-exponential-idea-for-blockchain-exposure <p>Bitcoin has been in the spotlight for both positive and negative reasons this year, but even with increased chatter about the world&#39;s largest cryptocurrency, blockchain and related investments seem to be overlooked.</p> <h3>What Happened</h3> <p>As has been previously noted, there are <a href="https://www.benzinga.com/markets/cryptocurrency/19/02/13116258/a-new-etf-combines-blockchain-cloud-and-other-technologies">several exchange traded funds</a> on the market today dedicated to blockchain theme. Others offer ample though indirect blockchain exposure, a group that includes the <strong>iShares Exponential Technologies ETF</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xt#NASDAQ">XT</a>).</p> <p>The $2.53 billion XT, which is almost 5 years old and holds almost 200 stocks, tracks the Morningstar Exponential Technologies Index.</p> <p>&ldquo;The Morningstar Exponential Technologies Index focuses on finding high-growth companies that are in the early stages of developing technologies that are expected to have a broad impact on society and transform how we live and work,&rdquo; ...</p><p><a href=https://www.benzinga.com/markets/cryptocurrency/19/10/14632013/an-exponential-idea-for-blockchain-exposure alt=An Exponential Idea For Blockchain Exposure>Full story available on Benzinga.com</a></p> Bitcoin Blockchain Cryptocurrency Long Ideas Sector ETFs XT Top Stories Markets Tech Trading Ideas ETFs XT Long Ideas Sector ETFs Cryptocurrency Top Stories Markets Tech Trading Ideas ETFs Benzinga Tue, 22 Oct 2019 14:25:06 +0000 ETF Professor 14632013 at https://www.benzinga.com 14 Stocks With The Highest Long-Term Projected Earnings Growth Rates https://www.benzinga.com/trading-ideas/long-ideas/19/10/14635678/14-stocks-with-the-highest-long-term-projected-earnings-growth-rates <p>Value investors often look at price-to-earnings ratios to gauge how cheaply a stock is priced. However, some of the stocks with the lowest PE ratios in the S&amp;P 500 have earnings that are trending in the wrong direction.</p> <p><strong>Macy&#39;s Inc</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/m#NYSE">M</a>), for example, has a PE of around 5. But it has struggled to maintain revenue and profits in recent years, and it&rsquo;s poor stock returns reflect those struggles.</p> <p>Instead of looking at the past or the preset, long-term investors can get ahead of the curve by looking at which stocks are expected to grow earnings the most over the next few years. By focusing on earnings growth rather than revenue growth, investors are weeding out growth stocks that haven&rsquo;t proven their business model can be consistently profitable. If long-term earnings ...</p><p><a href=https://www.benzinga.com/trading-ideas/long-ideas/19/10/14635678/14-stocks-with-the-highest-long-term-projected-earnings-growth-rates alt=14 Stocks With The Highest Long-Term Projected Earnings Growth Rates>Full story available on Benzinga.com</a></p> AIG AMZN BKR CHTR FSLR FTI INCY Long Ideas M MRO NFLX NOV PXD RE UA UAA VRTX Education Top Stories Trading Ideas General BKR US0571491069 AMZN US0231351067 FSLR US3364331070 INCY US45337C1027 NFLX US64110L1061 VRTX US92532F1003 AIG US0268747849 FTI US30249U1016 M US55616P1049 MRO US5658491064 NOV US6370711011 PXD US7237871071 RE BMG3223R1088 UA US9043111072 CHTR US16117M3051 UAA Long Ideas Education Top Stories Trading Ideas General Benzinga Tue, 22 Oct 2019 14:15:08 +0000 Wayne Duggan 14635678 at https://www.benzinga.com Biogen Plans Filing For Failed Alzheimer's Drug After New Analysis https://www.benzinga.com/general/biotech/19/10/14635164/biogen-plans-filing-for-failed-alzheimers-drug-after-new-analysis <p><strong>Biogen Inc </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/biib#NASDAQ">BIIB</a>) shares, which suffered a severe setback in early 2019 after the company&#39;s Alzheimer&#39;s program flopped, were&nbsp;seeing a resurgence Tuesday.&nbsp;</p> <p>The stock fell under the psychological barrier of $300 March 21, when the company and its development partner <strong>Eisai Co., Ltd </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/esaly#OTC">ESALY</a>) <a href="https://www.benzinga.com/general/biotech/19/03/13400790/biogen-plunges-25-after-company-discontinues-alzheimers-drug-study"> announced </a> their decision to shelve two late-stage studies dubbed ENGAGE and EMERGE that evaluated the efficacy and safety of aducanumab in patients with mild cognitive impairment due to Alzheimer&#39;s disease and mild Alzheimer&#39;s disease dementia.</p> <p>After moving roughly sideways in a range of $215.78-$246.99, Biogen stock has reclaimed the $300 level, with the catalyst being a startling about-face with respect to its Alzheimer&#39;s program.</p> <h3>Alzheimer&#39;s Program Revived&nbsp;</h3> <p>Biogen said Tuesday it plans to file a BLA for aducanumab for the treatment of early Alzheimer&#39;s disease following consultation with the FDA.</p> <p>The decision was based on a new analysis conducted by Biogen ...</p><p><a href=https://www.benzinga.com/general/biotech/19/10/14635164/biogen-plans-filing-for-failed-alzheimers-drug-after-new-analysis alt=Biogen Plans Filing For Failed Alzheimer&#039;s Drug After New Analysis>Full story available on Benzinga.com</a></p> alzheimer's BIIB Biotech Earnings ESALY News FDA Top Stories Trading Ideas General BIIB US09062X1037 ESALY News Earnings Biotech FDA Top Stories Trading Ideas General Benzinga Tue, 22 Oct 2019 13:12:04 +0000 Shanthi Rexaline 14635164 at https://www.benzinga.com Another ETF Avenue For Video Game Access https://www.benzinga.com/analyst-ratings/analyst-color/19/10/14632203/another-etf-avenue-for-video-game-access <p>With the video gaming industry ascending to stratospheric heights (by some estimates $152 billion this year), issuers of exchange traded fund are meeting investor demand for nuanced funds focusing on that growth. One of the newer entrants to that fray is the <strong>Defiance NextGen Video Gaming ETF </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vidg#NYSE">VIDG</a>).</p> <h3>What Happened</h3> <p>VIDG, which tracks the BlueStar Next Gen Video Gaming Index, a modified cap-weighted index with a heavy emphasis on the hardware (consoles) and software (game publishers) sides of the video game business.</p> <p>Those are compelling opportunities for investors because new games are among the pistons powering the industry and a major console upgraded cycle is forecast for 2020 as <strong>Microsoft </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>) and Sony (NYSE: <a class="ticker" ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/19/10/14632203/another-etf-avenue-for-video-game-access alt=Another ETF Avenue For Video Game Access>Full story available on Benzinga.com</a></p> Analyst Color ATVI EA eSports Long Ideas MSFT PlayStation Sector ETFs SNE TTWO video games VIDG xbox Tech Trading Ideas ETFs ATVI US00507V1098 EA MSFT US5949181045 TTWO US8740541094 SNE US8356993076 VIDG Long Ideas Sector ETFs Analyst Color Tech Trading Ideas ETFs Benzinga Tue, 22 Oct 2019 13:03:38 +0000 ETF Professor 14632203 at https://www.benzinga.com The Daily Biotech Pulse: Biogen Alzheimer's Program Back On Track, Novartis Reports Strong Quarter, Takeda In-Licenses Autoimmune Disorder Drug https://www.benzinga.com/general/biotech/19/10/14633980/the-daily-biotech-pulse-biogen-alzheimers-program-back-on-track-novartis-reports-strong-quarter-t <p>The following is a roundup of top developments in the biotech space over the last 24 hours:</p> <h3>Scaling The Peaks</h3> <p>(Biotech stocks that hit 52-week highs Oct. 21.)</p> <ul> <li><strong>Aprea Therapeutics Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apre#NASDAQ">APRE</a>)</li> <li><strong>AVITA MED LTD/S ADR </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rcel#NASDAQ">RCEL</a>)</li> <li><strong>Celgene Corporation </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/celg#NASDAQ">CELG</a>)</li> <li><strong>Constellation Pharmaceuticals Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cnst#NASDAQ">CNST</a>)</li> <li><strong>The Medicines Company </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdco#NASDAQ">MDCO</a>)</li> <li><strong>Natera Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntra#NASDAQ">NTRA</a>)</li> <li><strong>Seattle Genetics, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgen#NASDAQ">SGEN</a>) (<a href="https://www.benzinga.com/general/biotech/19/10/14626858/seattle-genetics-rallies-to-record-high-on-positive-results-from-midstage-breast-cancer-study">announced </a> positive Phase 2 results for breast cancer drug)</li> </ul> <h3>Down In The Dumps</h3> <p>(Biotech stocks that hit 52-week lows Oct. 21.)</p> <ul> <li><strong>Adaptive Biotechnologies Corp </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adpt#NASDAQ">ADPT</a>)</li> <li><strong>Arbutus Biopharma Corp </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abus#NASDAQ">ABUS</a>)</li> <li><strong>Assertio Therapeutics Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asrt#NASDAQ">ASRT</a>) (announced receipt of CRL by its development partner West Therapeutic for its injectable formulation of long-acting cosyntropin.)</li> <li><strong>Auris Medical Holding Ltd </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ears#NASDAQ">EARS</a>)</li> <li><strong>BioSpecifics Technologies Corp. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bstc#NASDAQ">BSTC</a>)</li> <li><strong>Cocrystal Pharma Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cocp#NASDAQ">COCP</a>)</li> <li><strong>Diffusion Pharmaceuticals Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dffn#NASDAQ">DFFN</a>)</li> <li><strong>Fulcrum Therapeutics Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>)</li> <li><strong>PDS Biotechnology Corp </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pdsb#NASDAQ">PDSB</a>)</li> <li><strong>Precision BioSciences Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dtil#NASDAQ">DTIL</a>)</li> <li><strong>Pulmatrix Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pulm#NASDAQ">PULM</a>)</li> <li><strong>Sophiris Bio Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sphs#NASDAQ">SPHS</a>)</li> <li><strong>Strongbridge Biopharma plc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sbbp#NASDAQ">SBBP</a>)</li> <li><strong>Trinity Biotech plc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trib#NASDAQ">TRIB</a>)</li> <li><strong>X T L Biopharmaceuticals Ltd </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xtlb#NASDAQ">XTLB</a>)</li> </ul> <p><em>See also:&nbsp;<a href="https://www.benzinga.com/general/biotech/19/10/14579904/biotech-stock-on-the-radar-assessing-miratis-oncology-franchise-with-an-eye-on-multiple-readouts">Biotech Stock On The Radar: Assessing Mirati&#39;s Oncology Franchise With An Eye On Multiple Readouts </a></em></p> <h3>Novartis Posts Higher Q3 Sales, Lifts Guidance&nbsp;</h3> <p><strong>Novartis AG </strong>(NYSE: <a class="ticker" ...</p><p><a href=https://www.benzinga.com/general/biotech/19/10/14633980/the-daily-biotech-pulse-biogen-alzheimers-program-back-on-track-novartis-reports-strong-quarter-t alt=The Daily Biotech Pulse: Biogen Alzheimer&#039;s Program Back On Track, Novartis Reports Strong Quarter, Takeda In-Licenses Autoimmune Disorder Drug>Full story available on Benzinga.com</a></p> ABUS ADPT APRE ASRT BIIB Biotech BSTC CELG CNST COCP DFFN DTIL Earnings EARS FULC IBB MDCO MRK News NLNK NTRA NVS PDSB PTGX PULM RCEL SBBP SGEN SPHS TAK TRIB VCYT XBI XTLB FDA Trading Ideas XBI US78464A8707 BIIB US09062X1037 BSTC US0909311062 CELG US1510201049 IBB US4642875565 MDCO US5846881051 SGEN US8125781026 TRIB US8964383066 MRK US58933Y1055 NVS US66987V1098 CNST XTLB NLNK APRE SPHS VCYT ADPT EARS COCP PULM NTRA ABUS SBBP DFFN TAK PTGX ASRT DTIL PDSB FULC RCEL News Earnings Biotech FDA Trading Ideas Benzinga Tue, 22 Oct 2019 11:51:16 +0000 Shanthi Rexaline 14633980 at https://www.benzinga.com 4 Industrials Stocks Moving In Tuesday's Pre-Market Session https://www.benzinga.com/news/19/10/14634010/4-industrials-stocks-moving-in-tuesdays-pre-market-session <div class="output_subarea output_markdown rendered_html"> <h3 id="gainers">Gainers</h3> <ul> <li><strong>United Technologies, Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/utx#NYSE">UTX</a>) stock moved upwards by 0.8% to $139.40 during Tuesday&#39;s pre-market session. The market cap stands at $117.8 billion. The most recent ...</li></ul></div><p><a href=https://www.benzinga.com/news/19/10/14634010/4-industrials-stocks-moving-in-tuesdays-pre-market-session alt=4 Industrials Stocks Moving In Tuesday&#039;s Pre-Market Session>Full story available on Benzinga.com</a></p> ABB BIMI GOGL Industrials Stocks Pre-Market Movers News Top Gainers UTX Movers & Shakers Pre-Market Outlook Markets Movers Trading Ideas General ABB US0003752047 UTX US9130171096 BIMI GOGL News Movers & Shakers Pre-Market Outlook Markets Movers Trading Ideas General Benzinga Tue, 22 Oct 2019 11:33:44 +0000 Lisa Levin 14634010 at https://www.benzinga.com 8 Healthcare Stocks Moving In Tuesday's Pre-Market Session https://www.benzinga.com/news/19/10/14633930/8-healthcare-stocks-moving-in-tuesdays-pre-market-session <h3 id="gainers">Gainers</h3> <ul> <li><strong>Biogen, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/biib#NASDAQ">BIIB</a>) stock increased by 35.1% to $302.01 during Tuesday&#39;s pre-market session. The market cap seems to be at $43.5 billion. The most recent rating by Bank of America, on October 17, is at Underperform, with a price target of $200.00.</li> <li><strong>SELLAS Life Sciences, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sls#NASDAQ">SLS</a>) stock rose 7.3% to $0.14. The market cap stands at $27.4 million.</li> <li><strong>Bionano Genomics, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bngo#NASDAQ">BNGO</a>) stock surged 3.7% to $1.12. The market cap stands ...</li></ul><p><a href=https://www.benzinga.com/news/19/10/14633930/8-healthcare-stocks-moving-in-tuesdays-pre-market-session alt=8 Healthcare Stocks Moving In Tuesday&#039;s Pre-Market Session>Full story available on Benzinga.com</a></p> BIIB BMY BNGO FMS Healthcare Stocks Pre-Market Movers MRK News ONCE QGEN SLS Top Gainers Movers & Shakers Pre-Market Outlook Markets Movers Trading Ideas General BIIB US09062X1037 QGEN NL0000240000 BMY US1101221083 FMS US3580291066 MRK US58933Y1055 SLS ONCE BNGO News Movers & Shakers Pre-Market Outlook Markets Movers Trading Ideas General Benzinga Tue, 22 Oct 2019 11:30:27 +0000 Lisa Levin 14633930 at https://www.benzinga.com